Technical Analysis for NGEN - Nervgen Pharma Corp
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Support | Bullish | -8.10% | |
| Spinning Top | Other | -8.10% | |
| Bollinger Band Squeeze | Range Contraction | -8.10% | |
| Narrow Range Bar | Range Contraction | -8.10% |
| Alert | Time |
|---|---|
| Down 1 ATR | about 19 hours ago |
| Down 5% | about 19 hours ago |
| Fell Below Lower Bollinger Band | about 19 hours ago |
| Fell Below Previous Day's Low | about 20 hours ago |
| 2x Volume Pace | about 20 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2024-05-13
NervGen Pharma Corp. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of nerve damage. Its product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University of Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Pharma Pharmaceutical Clinic Pharmaceutical Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Pharma Pharmaceutical Clinic Pharmaceutical Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.98 |
| 52 Week Low | 1.58 |
| Average Volume | 112,958 |
| 200-Day Moving Average | 2.240 |
| 50-Day Moving Average | 2.263 |
| 20-Day Moving Average | 2.095 |
| 10-Day Moving Average | 2.088 |
| Average True Range | 0.139 |
| RSI (14) | 40.12 |
| ADX | 24.72 |
| +DI | 14.825 |
| -DI | 25.348 |
| Chandelier Exit (Long, 3 ATRs) | 2.004 |
| Chandelier Exit (Short, 3 ATRs) | 2.286 |
| Upper Bollinger Bands | 2.255 |
| Lower Bollinger Band | 1.934 |
| Percent B (%b) | -0.01 |
| BandWidth | 15.316 |
| MACD Line | -0.061 |
| MACD Signal Line | -0.068 |
| MACD Histogram | 0.0075 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.155 | ||||
| Resistance 3 (R3) | 2.180 | 2.130 | 2.118 | ||
| Resistance 2 (R2) | 2.130 | 2.073 | 2.118 | 2.105 | |
| Resistance 1 (R1) | 2.030 | 2.037 | 2.005 | 2.005 | 2.092 |
| Pivot Point | 1.980 | 1.980 | 1.968 | 1.968 | 1.980 |
| Support 1 (S1) | 1.880 | 1.923 | 1.855 | 1.855 | 1.768 |
| Support 2 (S2) | 1.830 | 1.887 | 1.818 | 1.755 | |
| Support 3 (S3) | 1.730 | 1.830 | 1.743 | ||
| Support 4 (S4) | 1.705 |
